Par Drugs And Chemicals Limited
Par Drugs And Chemicals Limited (PAR) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
pardrugs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 22 Cr | 26 Cr | 29 Cr | 29 Cr |
| Operating expenses (approx.) | 20 Cr | 22 Cr | 23 Cr | 23 Cr |
| EBITDA | 2 Cr | 4 Cr | 6 Cr | 6 Cr |
| OPM % | 10.9% | 13.7% | 21.2% | 20.7% |
| Other income | 0.79 Cr | 2 Cr | 0.48 Cr | 1 Cr |
| Interest | 0.02 Cr | 0.02 Cr | 0.05 Cr | 0.01 Cr |
| Depreciation | 0.92 Cr | 0.90 Cr | 0.94 Cr | 0.93 Cr |
| Profit before tax | 2 Cr | 4 Cr | 6 Cr | 6 Cr |
| Tax % | 27.5% | 25.7% | 25.6% | 25.5% |
| Net profit | 2 Cr | 3 Cr | 4 Cr | 5 Cr |
| EPS (₹) | ₹1.34 | ₹2.70 | ₹3.36 | ₹3.90 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 101 Cr | Sign in for TTM |
| Operating expenses (approx.) | 81 Cr | Sign in for TTM |
| EBITDA | 20 Cr | Sign in for TTM |
| OPM % | 19.3% | Sign in for TTM |
| Other income | 2 Cr | Sign in for TTM |
| Interest | 0.08 Cr | Sign in for TTM |
| Depreciation | 4 Cr | Sign in for TTM |
| Profit before tax | 18 Cr | Sign in for TTM |
| Tax % | 25.5% | Sign in for TTM |
| Net profit | 13 Cr | Sign in for TTM |
| EPS (₹) | ₹10.86 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 12 Cr |
| Reserves | 87 Cr |
| Borrowings | — |
| Other liabilities | 20 Cr |
| Total liabilities | 119 Cr |
| Fixed assets (net) | 39 Cr |
| CWIP | 0 Cr |
| Investments | 25 Cr |
| Loans & advances | 0.10 Cr |
| Inventories | 6 Cr |
| Trade receivables | 17 Cr |
| Cash & bank | 28 Cr |
| Other assets | 5 Cr |
| Total assets | 119 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 16 Cr |
| Cash from investing | -25 Cr |
| Cash from financing | 0 Cr |
| Net cash flow | -9 Cr |
| Free cash flow (OCF − Capex) | 15 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 18.2% |
| ROE % | 13.5% |
| Debtor days | 60 |
| Inventory days | 56 |
| Days payable | 101 |
| Cash conversion cycle | 16 |
| Debt / equity | 0.00 |
| Current ratio | 3.31 |
| Net debt / EBITDA | -1.41 |